Clinical Trials Logo
  1. Home
  2. Methamphetamine Abuse
  3. NCT05971043
  4. Details
NCT05971043 Clinical Trial

Skin Disease in Methamphetamine Abuse

Methamphetamine Abuse Clinical Trial

Official title:
Skin Disorders in Patients Using Methamphetamine

Clinical Trial Details — Status: Not yet recruiting

Administrative data
NCT number NCT05971043
Other study ID # meth addiction
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date August 3, 2023
Est. completion date September 20, 2024

Study information
Verified date July 2023
Source Assiut University
Contact asmaa mohamed, master
Phone +201097507017
Email amelnakeeb@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

1. To detect the skin diseases in patients using methamphetamine

Description:

Methamphetamine is a stimulant drug that associated with a broad spectrum of health conditions, include addiction, mental health disorders, and overdose. The Drug Enforcement Agency (DEA) classifies it as a Schedule II drug. This means that the drug has a high potential for misuse. The drug is also called crystal meth, ice, and blue. Methamphetamine use has increased in Egypt especially in upper Egypt. Literature on cutaneous manifestations among methamphetamine users is limited, although cellulitis, delusion of parasitosis (DOP), hyperhidrosis, formication and prurigo nodularis (PN) have been attributed to methamphetamine users. While the relationship between skin lesions and substance use in not fully defined, there is some evidence that points to the development of these itchy, red lesion also known as meth sore after meth use. Meth sores often look like small round red patches on your skin, they can often be confused with acne when they appear on the face or a rash when they appear on other parts of the body. Meth sores form as a result of heavy meth misuse. other signs of meth abuse at the stage where sores likely to develop include: - Weight loss - Paranoia - Hallucinations - Aggressive behavior - Being easily distracted - Tooth and gum decay - Changes in brain structure

Recruitment information / eligibility
Status Not yet recruiting
Enrollment 500
Est. completion date September 20, 2024
Est. primary completion date August 20, 2024
Accepts healthy volunteers
Gender All
Age group 14 Years to 75 Years
Eligibility Inclusion Criteria: - Patients using methamphetamine Exclusion Criteria: - 1. Pregnant and lactating patients. 2. Patients with chronic diseases

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Assiut University

References & Publications (1)

Barnes AJ, Smith ML, Kacinko SL, Schwilke EW, Cone EJ, Moolchan ET, Huestis MA. Excretion of methamphetamine and amphetamine in human sweat following controlled oral methamphetamine administration. Clin Chem. 2008 Jan;54(1):172-80. doi: 10.1373/clinchem.2007.092304. Epub 2007 Nov 2. — View Citation

Outcome
Type Measure Description Time frame Safety issue
Primary skin disorders in patients using methamphetamine questionnaire-based study To detect the skin diseases and manifestation appears in patients using methamphetamine baseline
See also
  Status Clinical Trial Phase
Completed NCT05916989 - Stimulant Use and Methylation in HIV
Recruiting NCT04927143 - Encouraging Abstinence Behavior in a Drug Epidemic Phase 2
Completed NCT03226223 - Pharmacogenetics of Naltrexone for Stimulant Abuse Phase 2
Not yet recruiting NCT05593796 - Cognitive Behavioral Therapy(CBT) in Treatment of Methamphetamine Use Disorder N/A
Completed NCT02907853 - Contingency Management for Meth in South Africa Methamphetamine Abuse in South Africa N/A
Recruiting NCT04616625 - Cardiovascular Effects of Prenatal Methamphetamine Exposure
Completed NCT04061941 - Change in Cognitive Function in Stimulant Users
Completed NCT01967381 - Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse Early Phase 1
Terminated NCT01019707 - Safety Assessment of Atomoxetine With MA IV Administration Phase 1
Completed NCT01011829 - Varenicline vs Placebo for the Treatment of Methamphetamine Dependence Phase 2
Active, not recruiting NCT04706624 - Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics N/A
Recruiting NCT05700994 - Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM) N/A
Completed NCT04109014 - FASTLANE II: Reducing Sex, Drug, and Mental Health Risk N/A
Completed NCT03336866 - Study of Antibody for Methamphetamine Outpatient Therapy Phase 1/Phase 2
Completed NCT01822132 - Risky Decision Making in Methamphetamine Users: The Role of Opioid Blockade N/A
Completed NCT01062451 - An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence Phase 1
Not yet recruiting NCT06233799 - Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder Phase 3
Recruiting NCT05521854 - Contingency Management for Drug Use: Does Age Matter? N/A
Completed NCT01063205 - NAC as a Potential Treatment for Methamphetamine Dependence Phase 1
Not yet recruiting NCT05334914 - ACT for Methamphetamine Use Disorder in Women and Gender Non-Conforming Individuals N/A